OncoDNA, a Gosselies, Belgium-based healthcare technology company focusedd on precision medicine, raised €19m ($20m) in Series B equity financing.
The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank with the support of SFPI-FPIM. Historical shareholders together with CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW have also participated.
The new funding will support rapid international growth, accelerate software development and hiring initiatives.
Led by Jean-Pol Detiffe, CEO, and Pierre Flamant, CFO, OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database. This analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide, it provides them with interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials.
The company also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines.
OncoDNA employs 50 employees in 4 countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.